| 5.55 0.22 (4.13%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.48 |
1-year : | 7.57 |
| Resists | First : | 5.55 |
Second : | 6.48 |
| Pivot price | 5.15 |
|||
| Supports | First : | 4.74 |
Second : | 4.24 |
| MAs | MA(5) : | 5.31 |
MA(20) : | 5.02 |
| MA(100) : | 5.02  |
MA(250) : | 4.93 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 95.2 |
D(3) : | 90.5 |
| RSI | RSI(14): 66.6 |
|||
| 52-week | High : | 11.89 | Low : | 3.16 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CING ] has closed above the upper band by 3.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.56 - 5.58 | 5.58 - 5.6 |
| Low: | 5.31 - 5.34 | 5.34 - 5.37 |
| Close: | 5.51 - 5.55 | 5.55 - 5.59 |
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its pipeline for ADHD are two drug candidates: CTx-1301 (dexmethylphenidate), which is currently progressing through Phase 3 clinical trials, and CTx-1302 (dextroamphetamine). The company is also engaged in the advancement of CTx-2103, a candidate intended for the management of anxiety disorders. Founded in 2012, Cingulate Inc. maintains its corporate headquarters in Kansas City, Kansas.
Fri, 21 Aug 2026
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Thu, 20 Aug 2026
CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52 - Bitget
Thu, 13 Aug 2026
Cingulate Inc. Reports Second Quarter 2026 Financial - GlobeNewswire
Thu, 13 Aug 2026
Cingulate’s ADHD Drug Patent Protects Its Formulation Through 2042 - Stock Titan
Thu, 30 Jul 2026
Cingulate's ADHD candidate improved scores at all three doses - Stock Titan
Thu, 02 Jul 2026
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E® - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 13 (M) |
| Held by Insiders | 30.5 (%) |
| Held by Institutions | 10.5 (%) |
| Shares Short | 1,680 (K) |
| Shares Short P.Month | 1,760 (K) |
| EPS | -4.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.58 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -69.7 % |
| Return on Equity (ttm) | -225.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.73 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -20 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -1.29 |
| PEG Ratio | 0 |
| Price to Book value | 3.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.83 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|